白雲山(00874.HK):子公司王老吉藥業獲得藥物臨牀試驗補充申請批准通知書
格隆匯1月17日丨白雲山(00874.HK)公佈,公司子公司廣州王老吉藥業股份有限公司(以下簡稱"王老吉藥業")於2024年1月16日收到國家藥品監督管理局(以下簡稱"國家藥監局")頒發的藥物臨牀試驗補充申請批准通知書。根據《中華人民共和國藥品管理法》及有關規定,經審查,2023年10月18日受理的克感利咽口服液符合藥品註冊的有關要求,在進一步完善臨牀試驗方案的基礎上,同意開展用於兒童人羣的臨牀試驗。
2022年,王老吉藥業克感利咽口服液銷售額為人民幣3,540.63萬元。目前國內外尚無兒童克感利咽口服液的同類產品上市,無其國內外銷售數據。除王老吉藥業生產的克感利咽口服液外,中國境內上市的克感利咽顆粒的生產廠家有葵花葯業集團(襄陽)隆中有限公司、臨江市宏大藥業有限公司等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.